This roundup includes a selection of abstracts on early and metastatic breast cancer presented at the 2024 San Antonio Breast ...
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
Interleukin-2 (IL-2) is a well-known cytokine that plays a crucial role in stimulating immune cells, including natural killer (NK) cells and cytotoxic T cells. It has been studied as an immunotherapy ...
A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...
Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
On Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA ...
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re covering the American Society of Hematology (ASH) Annual Meeting, Dec. 7-10 in San ...
Then, in September, AZ revealed a miss in a trial of patients with newly diagnosed metastatic triple-negative breast cancer ...
Top Forbes | SHOOK financial advisors and Wall Street investment firms have pledged more than $500,000 toward development of ...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...